Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.62 Analyst target: $23.55 Upside: 798.85%
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of small molecule inhibitor for cancer patients. The company is headquartered in South San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.